![]() Methods: A partitioned survival model was adopted to predict the course of disease in advanced NSCLC patients on TC or PC from the perspective of the Chinese healthcare system over a 10-year horizon. Given the high cost of combination therapy, a cost-effectiveness analysis of toripalimab plus chemotherapy (TC) versus chemotherapy alone (PC) for the first-line treatment of patients with advanced NSCLC is required. ![]() However, whether it is cost-effective remains unknown. The CHOICE-01 trial (identifier: NCT 03856411) demonstrated that toripalimab plus chemotherapy can significantly improve the clinical outcomes of advanced non-small cell lung cancer (NSCLC) patients. ![]() 5Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Chinaīackground: Toripalimab is the first domestic anti-tumor programmed death 1 antibody marketed in China.4Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, China.3Department of Research Management, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, China.2Department of Drug Clinical Trial Institution, Fujian Cancer Hospital, Fuzhou, Fujian, China.1Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China.Mengdie Zhang 1, Kai Xu 1, Yingtao Lin 2, Chongchong Zhou 1,3, Yuwen Bao 4, Lingli Zhang 1* and Xin Li 1,4,5*
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |